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Abstract
Background: Epstein-Barr virus (EBV) is associated to the etio-pathogenesis of an increasing
number of tumors. Detection of EBV in pathology samples is relevant since its high prevalence in
some cancers makes the virus a promising target of specific therapies. RNA in situ hybridization
(RISH) is the standard diagnostic procedure, while polymerase chain reaction (PCR)-based
methods are used for strain (EBV type-1 or 2) distinction. We performed a systematic comparison
between RISH and PCR for EBV detection, in a group of childhood B-cell Non-Hodgkin lymphomas
(NHL), aiming to validate PCR as a first, rapid method for the diagnosis of EBV-associated B-cell
NHL.
Methods: EBV infection was investigated in formalin fixed paraffin-embedded tumor samples of 41
children with B-cell NHL, including 35 Burkitt's lymphoma (BL), from Rio de Janeiro, Brazil, by in
situ hybridization of EBV-encoded small RNA (EBER-RISH) and PCR assays based on EBNA2
amplification.
Results: EBV genomes were detected in 68% of all NHL. Type 1 and 2 accounted for 80% and 20%
of EBV infection, respectively. PCR and RISH were highly concordant (95%), as well as single- and
nested-PCR results, allowing the use of a single PCR round for diagnostic purposes. PCR assays
showed a sensitivity and specificity of 96% and 100%, respectively, with a detection level of 1 EBV
genome in 5,000–10,000 EBV-negative cells, excluding the possibility of detecting low-number EBV-
bearing memory cells.
Conclusion: We describe adequate PCR conditions with similar sensitivity and reliability to RISH,
to be used for EBV diagnostic screening in high grade B-NHL, in "at risk" geographic regions.
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Background
Epstein-Barr (EBV) is a widespread human herpesvirus
mainly B-cell tropic but capable of infecting T-cells and
epithelial cells [1,2]. Initial exposure to EBV usually
occurs in the first decade of life producing persistent,
latent asymptomatic infection. EBV infects more than
90% of the healthy population and is maintained at low
copy numbers (1–50 × 10-6 cells) in memory B-cells [3,4].
EBV has been associated to the etio-pathogenesis of an
increasing number of cancers [1,2,5,6]. In developing
countries, prevalence of EBV may reach 80% in some neo-
plasms, thus, exploitation of EBV association for clinical
purposes and therapeutic interventions is of interest [7-
10].
Specific sensitive methods for detecting EBV infection are
based on in situ hybridization (ISH), Southern blotting
and PCR [11,12]. RNA-ISH (RISH) for detecting EBERs
(EBV transcripts highly expressed in latently infected cells)
is the standard procedure for EBV diagnosis allowing
identification and distinction of infected cell types
[13,14]. PCR-based methods are used for strain determi-
nation (type-1 or 2). However, when strictly standardized,
PCR may have an important role in EBV diagnosis and
management in high-grade non-Hodgkin lymphoma
(NHL), although systematic comparisons between RISH
and PCR approaches are scarce.
We present a comparison between RISH and a PCR
method for detecting and genotyping EBV infection in 41
children with B-cell NHL. We also describe PCR condi-
tions resulting in similar sensitivity and reliability to
RISH, to validate PCR as a first, rapid diagnostic method,
followed by RISH for the diagnosis of EBV-associated
NHL.
Methods
Patients and clinical samples
Forty-four children (1–15 years old), diagnosed with NHL
at the Instituto Nacional de Câncer (INCa), Rio de
Janeiro, Brazil, were studied. The Ethics committee of
INCa approved this study.
The sample included 38 Burkitt's lymphomas/L3-ALL
(BL), 2 Burkitt's-like lymphomas (BLL) and 4 diffuse large
B-cell lymphomas (DLBCL). Histopathological diagnosis
was revised according to the R.E.A.L classification [15]. In
41 cases, paraffin-embedded tumor tissue (PET) samples
were available for RISH/PCR comparisons. In 16 cases,
PET and fresh tumor samples were compared. In 9 cases,
bone marrow (BM) mononuclear cells and tumor mass
samples were studied simultaneously. BM infiltration was
assessed by morphological and molecular procedures.
Thirty peripheral blood (PB) samples from healthy
donors and 26 reactive lymph nodes from HIV-negative
patients without history of previous cancer, referred to the
laboratory for clonality detection, were used as controls.
EBER-1 RNA in situ hybridization
EBV infection was diagnosed by RISH using riboprobes
for EBER1 as described [16,17]. PET sections were depar-
affinized, rehydrated, digested with proteinase K, and
hybridized overnight at a concentration of 0.25 ng/μl of
the biotinylated probe. Detection was accomplished with
a streptavidin-alkaline phosphatase conjugate. Slides were
counterstained with methyl green and mounted with
resin. One case of EBV-positive Burkitt's lymphoma was
used as positive control; cells expressing EBER1 showed
dark nuclear staining. Analysis was performed blindly
respect to PCR assays.
PCR amplifications
High molecular weight (HMW) DNA was obtained by
conventional methods [18]. PET-DNA was extracted fol-
lowing strict measures to avoid cross-contamination. Suit-
ability of DNA for PCR amplifications was assessed in
single and multiplex reactions for amplifying four consti-
tutive genes, as described [19].
EBV genotyping was performed by nested-PCR [20]. The
first PCR reaction amplified a common region of EBNA2
followed by two separate nested reactions amplifying dis-
tinctive regions (Table 1). Single-PCR assays with both
type-1 and -2, specific primers were also performed. DNA
was amplified in 50 μl reactions containing 1.5 mM
MgCl2, gelatin 0.001%, 0.3 μM of each primer, 1U of Taq
Platinum DNA polymerase (Invitrogen) and, alternatively,
either 500 ng of HMW DNA, 5 μl of lysate or 1 μl of first
reaction for nested-PCR. Cycling conditions: First reac-
tion: 94°C 2 min, 35 cycles of 94°C 1 min, 52°C 90 sec,
72°C 4 min, followed by 72°C for 10 min. Nested reac-
tion: 94°C, 2 min, 35 cycles of 94°C 30 sec, 52°C 1 min,
72°C 2 min, followed by 72°C for 10 min.
Reproducibility was assessed through a blind PCR test
with two separate DNA extracts obtained from each of 15
different PET samples. We also compared HMW-DNA and
PET-DNA amplifications of 9 patients. The EBV-negative
Ramos and the EBV-positive Raji and BC1 cell lines were
used as negative and positive controls for type-1 and type-
2 PCR assays, respectively. PCR reactions were performed
at least twice, in a PTC-100TM (MJ Research. Inc., Water-
town, MA) thermocycler.
Sensitivity assays were performed with DNA extracts from
sequential, 10-fold dilutions of Namalwa cells containing
two integrated EBV genomes per cell [21] in an EBV-nega-
tive background.Diagnostic Pathology 2006, 1:17 http://www.diagnosticpathology.org/content/1/1/17
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To test the possibility of EBV amplification in samples
lacking morphological or molecular evidence of malig-
nancy, BM aspirates and tumor samples from the same
patients were compared in 9 cases. Presence of clonal
immunoglobulin (IGH) rearrangements was investigated
using consensus primers (FR3-JH and FR2-JH) [19]. Once
identified in the tumor mass, clonal markers were investi-
gated in BM for detecting infiltration at the molecular
level.
Results
RISH detection and comparisons with PCR assays
Infection was detected in 28 of 41 of patients (68%). In
the first set of parallel assays, EBV was detected by RISH in
27/41 cases and by PCR in 28/41 cases. Discordant results
were one RISH-positive/PCR-negative and two RISH-neg-
ative/PCR-positive (7%). When both assays were repeated
in different samples of the same tumor mass, the RISH-
positive/PCR-negative case was confirmed while one
RISH-negative/PCR-positive was shown to be RISH-posi-
tive/PCR positive and the other, RISH-negative/PCR-neg-
ative. Considering RISH as the standard test for EBV
detection, RISH resulted in one false-negative case (sensi-
tivity 96%) while PCR produced one false-negative result,
corresponding to 96% sensitivity, 100% specificity, 100%
positive predictive value and 93% negative predictive
value.
Molecular detection
Amplifications of constitutive genes from PET-DNA were
successful in 38/41 samples (93%). Single and nested-
PCR assays for amplifying the EBNA2  gene were per-
formed in all samples (fig 1). Infection was detected in 28
of 41 (68%) cases. Analysis of EBV amplifications in the
PET-DNA samples showed three PCR-positive/RISH-posi-
tive cases in which constitutive genes could not be ampli-
fied by multi- or singleplex. In these samples, high levels
of DNA degradation did not seem to impair viral DNA
amplification since, in all cases, the 801 bp, first step- and
the 250/300 bp single- PCR products were amplified. A
comparison of RISH and PCR results is shown in Table 2,
which includes PCR results of cases with constitutive
amplification.
Nested and single PCRs, as well as blind PCR tests, with
two separate DNA extracts from 15 PET samples, were
completely concordant, as were comparisons of HMW-
DNA and PET-DNA amplifications.
EBV-DNA could be detected at a minimal dilution of 1
Namalwa cell in 2 × 104 EBV-negative cells by single PCR,
with a 0.5 log10 increase by nested PCR (fig 2).
Presence of EBV was investigated in HMW-DNA from 30
healthy PB and 26 polyclonal lymphoproliferations.
None of the PB and one reactive lymph node (3.8%)
showed positive results by single and nested EBV-PCR
assays. In the 9 BM aspirates from BL patients, the EBV
genome was detected only in BM samples infiltrated by
EBV-positive tumor cells (Table 3).
Discussion
One of the most striking characteristics of pediatric BL is
the variant frequency of EBV association in different geo-
graphic regions [5]. In tropical Africa it is almost always
EBV-related. Conversely, in sporadic BL in developed
countries, EBV association has been demonstrated in 15
to 30% of cases [5,22]. The association of BL and EBV in
developing countries is intermediate between the spo-
radic and endemic types [8,23,24]. In South America, a
high association of EBV and BL was reported in the North-
east of Brazil (~80%) [25-27], and a lower association was
observed in patients from Argentina and Chile [28-30]. In
the present study, we detected a frequency of EBV associa-
tion of 68% in 41 childhood NHL from Southeastern Bra-
zil, which is higher than in developed countries. Thus, the
use of EBV for identifying new therapy targets in poor-risk,
EBV-positive lymphomas is of interest, leading to an effort
to improve current EBV diagnosis.
EBER-RNA in situ hybridization is the standard for EBV
diagnosis in tumor cells [14] while PCR procedures are
used for EBV typing. Although the simplicity of PCR
might favor its adoption as a first-line method for diagno-
sis, its high sensitivity may produce false positive results
due to detection of EBV-positive memory cells and/or
non-tumor, bystander lymphocytes. However, the fre-
Table 1: Primers used for EBNA2 PCR typing
Primers Sequence (5'-3') Use in the PCR reaction EBNA-2 Location*
EBNA-2F TGGAAACCCGTCACTCTC 1st reaction sense 48572-89
EBNA-2I TAATGGCATAGGTGGAATG 1st reaction sntisense 49355-73
EBNA-2C AGGGATGCCTGGACACAAGA Nested reaction sense 48810-29
EBNA-2G GCCTCGGTTGTGACAGAG Nested reaction antisense type-1 49048-65
EBNA-2B TTGAAGAGTATGTCCTAAGG Nested reaction antisense type-2 2020-39#
* Sequence locations for type-1 correspond to B95.8 coordinates (Accession number V01555) and for type-2 (#) to AG876 isolate (Accession 
number K03332).Diagnostic Pathology 2006, 1:17 http://www.diagnosticpathology.org/content/1/1/17
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quency of EBV-positive memory cells in healthy seroposi-
tive individuals accounts for less than 1/50,000 in almost
all estimates [3,4,31] while BL and DLBCL are mainly
characterized by lymphoproliferation of monomorphic
cells carrying a high viral load when infected by EBV [31].
These observations prompted us to validate PCR assays
for EBV diagnosis in these high-grade NHL, where strictly
standardized PCR methods may have an important role.
First, in a high complexity center offering cancer care to a
large population, RISH is a second or third timeline
method, considered only after histopathological and
immunohistochemical diagnosis. The early definition of
EBV status is important in some situations, for instance, to
define the enrolment of a patient in a clinical protocol or
in a viral load monitoring study, or to proceed with bio-
logical studies on fresh material. Second, the financial
cost of RISH may be limiting in low-resource countries,
making the effort to develop a rationale for EBV diagnosis,
including PCR as a first-line, rapid approach followed by
RISH for confirmation, significant.
We present a specific and reliable method for EBV-detec-
tion and typing in clinical samples. The choice of PET-
DNA as PCR template aimed to make the results of both
methods comparable, and to test the reliability of PCR in
the most unfavorable technical conditions. Our compari-
sons of EBV detection by RISH and PCR showed that both
methods provided highly concordant data (95%) with the
same sensitivity (96%). The low EBV detection in reactive
lymphoproliferations (4%) also points to the suitability
of adopting PCR as a routine screening test, which can be
instrumented based on single round PCR, decreasing the
risks of potential cross-contamination.
Experiments of nested-PCR assays with Namalwa well-
preserved DNA showed the highest sensitivity of our
method. Even this sensitivity excluded the possibility of
detecting EBV-bearing memory cells in clinical samples,
reinforced by paired analyses of 9 BM and tumor samples,
in which EBV was detected by PCR only in cases showing
BM infiltration by EBV-positive tumor cells. It should be
Molecular analysis of EBV-positive and negative Non-Hodgkin lymphomas Figure 1
Molecular analysis of EBV-positive and negative Non-Hodgkin lymphomas. (A) Nested-PCR EBV genotyping. 
Expected sizes of nested PCR products were 250 bp (type-1) and 300 bp (type-2), amplified from an 801 bp fragment obtained 
in the first PCR reaction. Lane 1: Type-1 positive control (Raji cell line); lanes 2–3: EBV-positive type-1 patients; lane 4: Type-2 
positive control (BC1 cell line); lane 5: EBV-positive type-2 patient; lane 6: EBV negative patient; lane 7: negative control 
(Ramos cell line); lane 8: PCR control (without DNA). (B) DNA amplification testing by multiplex PCR of constitutive β-globin, 
β-actin and Glyceraldehide-3 phosphate dehydrogenase genes (from bottom to top) corresponding to patients and controls in A. 
2.5% agarose gel stained with ethidium bromide. M: molecular weight marker (100 bp ladder).Diagnostic Pathology 2006, 1:17 http://www.diagnosticpathology.org/content/1/1/17
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mentioned that the proposed diagnosis scheme depends
on the sensitivity of our PCR method, because a more sen-
sitive method might lead to a different conclusion.
In previous PCR typing studies in BL, concordant RISH/
PCR results were reported in RISH-positive cases that were
subsequently PCR-tested [23-30]. As no information was
provided on PCR results in EBER-negative cases, an
exceedingly high sensitivity of those EBV-specific PCR
methods, making them unsuitable for diagnostic pur-
poses, could not be assessed.
In this study, although only one viral gene was tested, viral
DNA appeared to be more efficiently amplified than PET
genomic DNA, raising the possibility that viral DNA
might be more resistant to degradation, probably due to a
differential effect of the tissue fixative on EBV DNA/pro-
tein complexes [32]. However, if PCR is used as a screen-
ing test, amplification of cellular genes should be
considered mandatory.
The molecular detection of EBV in lymphomas has not
produced coherent results due to biological heterogeneity
and to methodological differences [33-35]. The diagnostic
criteria recommended by the IARC-WHO [14] are appro-
priate for entities like HD, where the heterogeneity of clin-
ical subtypes and cell types justify this conservative
approach [35]. Molecular EBV detection should also be
Sensitivity assays Figure 2
Sensitivity assays. Namalwa cells (2 EBV genome per cell) were serially diluted in the EBV-negative cells of Ramos cell line. 
PCR results showed that the method is able to detect 1 EBV genome in a background of 5 × 103 (first reaction) (A) and 1 × 104 
negative cells (nested PCR) (B). 2.5% agarose gel stained with ethidium bromide.
Table 2: Comparison of EBV detection by RISH and PCR and EBV typing in children with NHL
EBV Detection EBV Typing
Diagnosis EBER-ISH+ (N = 41) PCR+ (N = 38*) Type-1 (% of infected) Type-2 (% of infected)
BL 25/35 21/32 18 3
BLL 0/2 0/2 0 0
DLCL 3/4 4/4 2 2
Total 28 (68%) 25 (66%) 20 (80%) 5 (20%)
* Only cases with amplification of cellular genes were used for calculation of frequenciesDiagnostic Pathology 2006, 1:17 http://www.diagnosticpathology.org/content/1/1/17
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cautiously considered in peripheral T-cell NHL and ana-
plastic large-cell lymphoma, since they comprise hetero-
geneous entities with uncertain clonality status [36,37].
Conclusion
The high correlation we observed between RISH and PCR
data suggests that EBV diagnosis could be updated for
lymphomas like BL and DLBCL, with PCR as a rapid
approach followed by RISH confirmation. This would be
adequate for EBV-diagnosis in developing regions, espe-
cially in areas where the epidemiological status of several
EBV-associated entities remains unclear [26,27].
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